Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- GMA-8003 - Provider product page

- Provider
- Green Mountain Antibodies
- Product name
- Anti-Factor VIII
- Antibody type
- Monoclonal
- Antigen
- Factor VIII
- Description
- GMA-8003 is a C2 domain specific antibody useful for detection of FVIII by ELISA. GMA-8003 is the designated cell line 2-117 as described by Meeks, S et al. in reference 1 and Summers, R et al. in reference 3.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- GMA-8003
- Vial size
- 0.1mg, 0.5mg
Submitted references Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.
Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Revision of the International Health Regulations. Progress Report, July 1997.
Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 1997 Jul 18;72(29):213-5
Summers RJ, Meeks SL, Healey JF, Brown HC, Parker ET, Kempton CL, Doering CB, Lollar P
Blood 2011 Mar 17;117(11):3190-8
Blood 2011 Mar 17;117(11):3190-8
Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P
Blood 2007 Dec 15;110(13):4234-42
Blood 2007 Dec 15;110(13):4234-42
Revision of the International Health Regulations. Progress Report, July 1997.
Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 1997 Jul 18;72(29):213-5
No comments: Submit comment
No validations: Submit validation data